HLB1-001 / Huons - LARVOL DELTA

Huons Lab speeds up developing short bowel syndrome treatment (Korea Biomedical Review) - "Huons Lab said Monday that its development of a long-lasting dual agonist peptide for short bowel syndrome (SBS) has gained additional momentum, as it was chosen as a state-subsidized project for growth technology....The ministry will give 130 million won ($119,000) to Huons Lab until 2021 to develop a dual-acting peptide that treats short gut....Huons Lab targets to develop a new drug with an increased half-life that allows a weekly dose. It plans to complete preclinical development by 2021 and enter phase 1 study in the following year."

Financing • New P1 trial • Preclinical • Short Bowel Syndrome